Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory <i>ALK</i> ‐positive NSCLC from a phase II study
Jing Zheng(Zhejiang University), Li Zhang(Jinan Stomatological Hospital), Yunpeng Yang(Sun Yat-sen University), Weineng Feng(First People's Hospital of Foshan), Giovanni Selvaggi, Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Shundong Cang(Henan University), Yi Hu(Union Hospital), Zhendong Zheng(General Hospital of Shenyang Military Region), Yanqiu Zhao(Henan Cancer Hospital), Jianying Zhou(First Affiliated Hospital Zhejiang University), Gang Wu(Hubei University of Chinese Medicine), Youling Gong(Dalian Medical University), Kewei Ma(Jilin University), Wei Song(Xuzhou Medical College), Zhilin Shen(Betta Pharmaceuticals (China)), Shijun Zhao(Second Hospital of Shandong University), Shanshan Xiao(Central South University), Yubiao Guo(Sun Yat-sen University), Jian Fang(Peking University), Jianhua Chen(Hunan Cancer Hospital), Qian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan Chen(China General Nuclear Power Corporation (China)), Tao Wang(Pfizer (United States)), Feng Ye(First Affiliated Hospital of Xiamen University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Zhuang Yu(Shanghai East Hospital), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Gaofeng Li(Sir Run Run Shaw Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Huijie Wang(Fudan University Shanghai Cancer Center), Jie Huang(Sun Yat-sen University), Ning Wu(Regeneron (United States)), Lieming Ding(Betta Pharmaceuticals (China)), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Xiaoqing Liu(Chinese PLA General Hospital), Wu Zhuang(Fujian Medical University), Jianya Zhou(First Affiliated Hospital Zhejiang University), Yang Wang(Shandong Normal University), Yiping Zhang(National Health and Family Planning Commission)
Cited by 9
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k